Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREAT ctDNA
2022-501453-36-00Phase 3Authorised
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2024
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of elacestrant in breast cancer (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Distant metastasis-free survival. Planned start Feb 2024; status: authorised.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-501453-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501453-36-00.